lipid-a has been researched along with palmatine* in 2 studies
2 other study(ies) available for lipid-a and palmatine
Article | Year |
---|---|
Evaluation of anti-sepsis activity by compounds with high affinity to lipid a from HuanglianJiedu decoction.
HuanglianJiedu decoction (HJD) is a classic prescription for heat-clearing away and detoxifying, which is used for the clinical treatment of sepsis, due to sepsis refers to the systemic inflammatory response induced by infection in western medicine, and infection belongs to the category of poison-heat syndrome in traditional Chinese medicine.. Previous study had elucidated the effective components from HJD with high affinity to lipid A, which can generate the release of pro-inflammatory-cytokines, resulting in sepsis. Now the anti-sepsis activities of these compounds were evaluated.. Immunofluorescence, immunohistochemical staining, ELISA and MTT methods were used to evaluated these compounds.. Immunofluorescence analysis evaluated the effects of compounds on the binding of FITC-LPS to RAW264.7 cells, and showed the fluorescence intensity was significant attenuated in geniposides, palmatine, baicalin and berberine groups (64 and 128 μg/mL) compared with model group (p < 0.05), which showed these compounds inhibit the combination of LPS with receptor of cells; immunohistochemical staining and ELISA method showed the TLR4 receptor expression, IL-6 and TNF-α levels were significant decreased in the groups treated with compounds, indicating that geniposides, baicalin, palmatine and berberine can play the role of anti-sepsis by inhibiting the expression of TLR4, the releasing of IL-6 and TNF-α; MTT assay showed that palmatine and berberine had a weak effect on cell viability, while others not, indicating that the compounds have protective activity.. It could be concluded the high affinity binding between these compounds and lipid A may be an important basis for its anti-LPS activity in vitro. Topics: Animals; Berberine; Berberine Alkaloids; Cell Line; Drugs, Chinese Herbal; Flavonoids; Interleukin-6; Iridoids; Lipid A; Lipopolysaccharides; Mice; RAW 264.7 Cells; Sepsis; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2017 |
The anti-sepsis activity of the components of Huanglian Jiedu Decoction with high lipid A-binding affinity.
Huanglian Jiedu Decoction (HJD), one of the classic recipes for relieving toxicity and fever, is a common method for treating sepsis in China. However, the effective components of HJD have not yet been identified. This experiment was carried out to elucidate the effective components of HJD against sepsis. Thus, seven fractions from HJD were tested using a biosensor to test their affinity for lipid A. The components obtained that had high lipid A-binding fractions were further separated, and their affinities to lipid A were assessed with the aid of a biosensor. The levels of LPS in the blood were measured, and pathology experiments were conducted. The LPS levels and mRNA expression analysis of TNF-α and IL-6 of the cell supernatant and animal tissue were evaluated to investigate the molecular mechanisms. Palmatine showed the highest affinity to lipid A and was evaluated by in vitro and in vivo experiments. The results of the in vitro and in vivo experiments indicated that the levels of LPS, TNF-α and IL-6 of the palmatine group were significantly lower than those of the sepsis model group (p<0.01). The group treated with palmatine showed strong neutralizing LPS activity in vivo. The palmatine group exhibited stronger protective activity on vital organs compared to the LPS-induced animal model. This verifies that HJD is a viable treatment option for sepsis given that there are multiple components in HJD that neutralize LPS, decrease the release of IL-6 and TNF-α induced by LPS, and protect vital organs. Topics: Animals; Berberine Alkaloids; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Humans; Interleukin-6; Lipid A; Lipopolysaccharides; Mice; Mice, Inbred BALB C; RAW 264.7 Cells; Sepsis; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2017 |